Latest Breaking News On - Recent corporate - Page 22 : vimarsana.com

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that.

United statesGary priceMichael boberTyra biosciencesAmy conradTodd harrisGeorge melkoPrnewswire tyra biosciences incSkeletal dysplasia programTyra biosciences incDrug administrationRegulatory affairsClinical developmentExchange commissionOrphan drug designationFibroblast growth factor receptor

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Q2 2023 DANYELZA® record net product revenues of $20.8 million, driving YoY growth of 112% and a 3% sequential increase compared to Q1 2023Managem.

United statesCourtney duganCompany selfBrazilian health regulatory agencyAmerican association for cancer researchCompany annual report on formMemorial sloan kettering cancer centerY mabs therapeutics incSciclone pharmaceuticalsAmerican society of clinical oncologySecurities exchangeGlobe newswirey mabs therapeutics incCompany quarterly report on formAbs therapeuticsThomas gadInterim chief executive

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United statesCourtney duganAmerican society of clinical oncologySciclone pharmaceuticalsCompany selfCompany annual report on formCompany quarterly report on formMemorial sloan kettering cancer centerSecurities exchangeGlobe newswirey mabs therapeutics incBrazilian health regulatory agencyY mabs therapeutics incAmerican association for cancer researchAbs therapeuticsThomas gadInterim chief executive

Context Therapeutics Reports Second Quarter 2023 Operating

Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June.

United statesJennifer minai azaryMartin lehrGina cestariHc wainwright coExchange commissionAmerican society of clinical oncology annual meetingContext therapeutics incCompany nasdaqInvestigational new drug applicationRecent corporateBiotechnology conferenceImmune cell engager virtual conferenceClinical oncology annual meetingPrivate securities litigation reform actMonths ended june

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.

Jami taylorDineshv patelExchange commissionInternational societies for investigative dermatologyEuropean hematology associationWorld congressDevelopment rd expensesProtagonist therapeutics incJanssen biotech incProtagonist therapeuticsRecent corporatePsoriasis areaSeverity indexInternational societiesInvestigative dermatologyCash equivalents